High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Gravesen, Eva ^a   Hofman Bang, Jacob ^a   Mace, Maria L ^b   Lewin, Ewa ^a,b   Olgaard, Klaus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chronic kidney disease; FGF23; Iron; Phosphate

Indexed keywords

CALCIUM ION; FERRIC CARBOXYMALTOSE; FERRITIN; FIBROBLAST GROWTH FACTOR 23; IRON; IRON DERIVATIVE; IRON ISOMALTOSIDE; PARATHYROID HORMONE; PHOSPHATE; TRANSFERRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; FERRITIN BLOOD LEVEL; HYPERPARATHYROIDISM; IRON BLOOD LEVEL; IRON THERAPY; MALE; NEPHRECTOMY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; RAT; UREMIA;

ANIMALS; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; INJECTIONS, INTRAVENOUS; IRON; MALE; PHOSPHATES; RATS; RATS, WISTAR; TREATMENT OUTCOME; UREMIA;

EID: 84891034737     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-281     Document Type: Article

References (39)

1. KDIGO clinical practice guideline for anemia in chronic kidney disease. Disease K, Improving Global Outcomes (KDIGO) Anemia Work Group, Kidney Int Suppl 2012 2 279 335
2. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Pizzi LT, Bunz TJ, Coyne DW, Goldfarb DS, Singh AK, Kidney Int 2008 74 1588 1595 10.1038/ki.2008.489 19034302
3. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, et al. J Am Soc Nephrol 2008 19 372 379 10.1681/ASN.2007050606 18216316
4. How can Erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis. Shirazian S, Grant C, Miller I, Fishbane S, Semin Dial 2013 26 534 536 23763675
5. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Lim CS, Vaziri ND, Kidney Int 2004 65 1802 1809 10.1111/j.1523-1755.2004.00580.x 15086920
6. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Zager RA, Johnson AC, Hanson SY, Kidney Int 2004 66 144 156 10.1111/j.1523-1755. 2004.00716.x 15200421
7. Impairment of transendothelial leukocyte migration by iron complexes. Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Horl WH, Sunder-Plassmann G, J Am Soc Nephrol 2003 14 2639 2644 10.1097/01.ASN.0000087087.61306.4A 14514743
8. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Zager RA, Johnson AC, Hanson SY, Wasse H, Am J Kidney Dis 2002 40 90 103 10.1053/ajkd.2002.33917 12087566
9. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post- hoc analysis of a prospective study. Prats M, Font R, Garcia C, Cabre C, Jariod M, Vea AM, BMC Nephrol 2013 14 167 10.1186/1471-2369-14-167 23902731
10. Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients. Hryszko T, Rydzewska-Rosolowska A, Brzosko S, Koc-Zorawska E, Mysliwiec M, Ther Apher Dial 2012 16 146 151 10.1111/j.1744-9987.2011.01037.x 22458393
11. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. Wolf M, Koch TA, Bregman DB, J Bone Miner Res 2013 28 1793 1803 10.1002/jbmr.1923 23505057
12. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Takeda Y, Komaba H, Goto S, Fujii H, Umezu M, Hasegawa H, et al. Am J Nephrol 2011 33 421 426 10.1159/000327019 21502756
13. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG, J Clin Endocrinol Metab 2009 94 2332 2337 10.1210/jc.2008-2396 19366850
14. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, et al. Bone 2009 45 814 816 10.1016/j.bone.2009.06.017 19555782
15. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Circulation 2002 106 2212 2217 10.1161/01.CIR.0000035250.66458.67 12390950
16. Regulation and function of the FGF23/klotho endocrine pathways. Martin A, David V, Quarles LD, Physiol Rev 2012 92 131 155 10.1152/physrev.00002.2011 22298654
17. Phosphate is a vascular toxin. Shroff R, Pediatr Nephrol 2013 28 583 593 10.1007/s00467-012-2347-x 23161206
18. Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. Olauson H, Lindberg K, Amin R, Jia T, Wernerson A, Andersson G, et al. J Am Soc Nephrol 2012 23 1641 1651 10.1681/ASN.2012010048 22878961
19. Update on fibroblast growth factor 23 in chronic kidney disease. Wolf M, Kidney Int 2012 82 737 747 10.1038/ki.2012.176 22622492
20. FGF23 induces left ventricular hypertrophy. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. J Clin Invest 2011 121 4393 4408 10.1172/JCI46122 21985788
21. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Nature 1997 390 45 51 10.1038/36285 9363890
22. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, et al. Proc Natl Acad Sci U S A 2011 108 1146 E1155 10.1073/pnas.1110905108 22006328
23. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ, J Clin Endocrinol Metab 2011 96 3541 3549 10.1210/jc.2011-1239 21880793
24. Bone remodelling is reduced by recovery from iron-deficiency anaemia in premenopausal women. Wright I, Blanco-Rojo R, Fernandez MC, Toxqui L, Moreno G, Perez-Granados AM, et al. J Physiol Biochem 2013 69 889 896 10.1007/s13105-013- 0266-3 23813442
25. Iron sensing and signalling. Evstatiev R, Gasche C, Gut 2012 61 933 952 10.1136/gut.2010.214312 22016365
26. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Schouten BJ, Doogue MP, Soule SG, Hunt PJ, Ann Clin Biochem 2009 46 167 169 10.1258/acb.2008.008151 19151167
27. Persistent downregulation of calcium- sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. Lewin E, Garfia B, Recio FL, Rodriguez M, Olgaard K, J Am Soc Nephrol 2002 13 2110 2116 10.1097/01.ASN.0000024439.38838.03 12138143
28. Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 secretory response to hypocalcemia in rats with intact parathyroid glands. Huan J, Olgaard K, Nielsen LB, Lewin E, J Am Soc Nephrol 2006 17 1923 1930 10.1681/ASN.2005101136 16707565
29. The parathyroid is a target organ for FGF23 in rats. Ben Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al. J Clin Invest 2007 117 4003 4008 17992255
30. FGF23 fails to inhibit uremic parathyroid glands. Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, et al. J Am Soc Nephrol 2010 21 1125 1135 10.1681/ASN.2009040427 20431039
31. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. White KE, Evans WE, O'Riordan JLH, Speer MC, Econs MS, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM, Nat Genet 2000 26 345 348 10.1038/81664 11062477
32. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Proc Natl Acad Sci U S A 2001 98 6500 6505 10.1073/pnas. 101545198 11344269
33. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. N Engl J Med 2003 348 1656 1663 10.1056/NEJMoa020881 12711740
34. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. Econs MJ, McEnery PT, J Clin Endocrinol Metab 1997 82 674 681 10.1210/jc.82.2.674 9024275
35. Structure, chemistry, and pharmacokinetics of intravenous iron agents. Danielson BG, J Am Soc Nephrol 2004 15 Suppl 2 93 S98 15585603
36. Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Isakova T, Xie H, Barchi-Chung A, Smith K, Sowden N, Epstein M, et al. Clin J Am Soc Nephrol 2012 7 820 828 10.2215/CJN.11721111 22383746
37. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM, Clin J Am Soc Nephrol 2011 6 383 389 10.2215/CJN.04730510 21030580
38. Biological variability of plasma intact and C-terminal FGF23 measurements. Smith ER, Cai MM, McMahon LP, Holt SG, J Clin Endocrinol Metab 2012 97 3357 3365 10.1210/jc.2012-1811 22689697
39. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, et al. J Clin Endocrinol Metab 2010 95 352 E357 10.1210/jc.2010-0589 20685863